| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Janus kinase 3 (JAK3), a tyrosine kinase essential for cytokine signaling through the common gamma chain (γc). JAK3 is primarily expressed in hematopoietic cells and is critical for lymphocyte development and function. ZM-39923 also inhibits tissue transglutaminase (TGM2), a calcium-dependent enzyme involved in protein cross-linking, cell adhesion, and apoptosis. Factor XIIIa is also inhibited. JAK3 inhibition blocks IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 signaling, while TGM2 inhibition affects extracellular matrix remodeling and cell survival.
|
|---|---|
| ln Vitro |
ZM39923 is a pIC50 of 7.1 JAK3 inhibitor. ZM39923 (compound 7) has no discernible inhibitory effect on tyrosine kinases Lck and CDK4 (pIC50<5.0), but it exhibits weak inhibitory effects on EGF-R and JAK1 (pIC50 are 5.6, 4.4, respectively) [1]. ZM39923 directly acts on purified TGM2, inhibiting the Ca2+-activated form of TGM2, and inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM[2]. ZM39923 has a similar effect to CCR7 antibodies in that it prevents JAK3 phosphorylation that is induced by CCL19. ZM39923 also considerably inhibits the migration and invasion of PCI-37B cells and blocks the rate of wound closure induced by CCL19 [3].
ZM-39923 is a potent JAK3 inhibitor with an IC50 of approximately 79 nM (pIC50 7.1). It also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM and Factor XIIIa with an IC50 of 25 nM. It shows weak inhibitory activity against EGFR (IC50 2.4 μM), JAK1 (IC50 40 μM), and CDK4 (IC50 10 μM). ZM-39923 blocks JAK3 phosphorylation induced by CCL19 and inhibits CCL19-induced migration and invasion of PCI-37B cells. It also inhibits TGM2 activity directly. |
| ln Vivo |
In vivo data for ZM-39923 are limited in publicly available literature. As a research tool, it has been primarily characterized in biochemical and cell-based assays. Its pharmacokinetic properties and in vivo efficacy have not been extensively studied. The compound's dual JAK3/TGM2 inhibition profile makes it attractive for evaluating in animal models of inflammatory diseases, fibrosis, and cancer. Further in vivo studies would be required to assess its therapeutic potential and optimal dosing regimens.
|
| Enzyme Assay |
For JAK3 kinase inhibition assays, recombinant JAK3 kinase domain is incubated with a peptide substrate in kinase assay buffer containing ATP. ZM-39923 is added at varying concentrations. Phosphorylated substrate is detected by ELISA or fluorescence polarization. For TGM2 inhibition assays, recombinant TGM2 is incubated with a fluorogenic substrate (e.g., CBZ-Gln-Gly) or [3H]putrescine and casein in the presence of calcium. ZM-39923 is added, and enzyme activity is measured by fluorescence or radioactivity.
|
| Cell Assay |
For cell-based assays, PCI-37B cells (a metastatic SCCHN cell line expressing CCR7) are cultured in DMEM with 10% FBS. ZM-39923 is added at varying concentrations. JAK3 phosphorylation induced by CCL19 is assessed by Western blot. Cell migration and invasion are measured using wound healing and Transwell assays. For TGM2 activity in cells, a fluorescent substrate is used. Cell viability is assessed by CCK-8 or MTT assay.
|
| Animal Protocol |
For in vivo evaluation, animal models of JAK3-dependent inflammation or TGM2-mediated fibrosis are used. ZM-39923 is administered intraperitoneally or orally at various doses. For inflammation models (e.g., collagen-induced arthritis, LPS-induced endotoxemia), inflammatory cytokine levels and tissue damage are assessed. For fibrosis models (e.g., bleomycin-induced lung fibrosis), collagen deposition is measured. Pharmacokinetic studies involve plasma sampling and LC-MS/MS quantification.
|
| References |
|
| Additional Infomation |
1-(2-Naphthyl)-3-[(benzyl)-propyl-2-ylamino]-1-propanone is a naphthalene compound. ZM-39923 is a small molecule that inhibits Janus kinase and human tissue transglutaminase (TGM2).
|
| Molecular Formula |
C23H25NO
|
|---|---|
| Molecular Weight |
331.45
|
| Exact Mass |
331.194
|
| CAS # |
273727-89-2
|
| Related CAS # |
ZM39923 hydrochloride;1021868-92-7
|
| PubChem CID |
3797
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.323
|
| tPSA |
20.31
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
412
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=C2C=CC=CC2=C1)CCN(C(C)C)CC3=CC=CC=C3
|
| InChi Key |
JSASWRWALCMOQP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25NO/c1-18(2)24(17-19-8-4-3-5-9-19)15-14-23(25)22-13-12-20-10-6-7-11-21(20)16-22/h3-13,16,18H,14-15,17H2,1-2H3
|
| Chemical Name |
3-[benzyl(propan-2-yl)amino]-1-naphthalen-2-ylpropan-1-one
|
| Synonyms |
ZM 39923 JAK3 inhibitor IV ZM-39923
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0170 mL | 15.0852 mL | 30.1705 mL | |
| 5 mM | 0.6034 mL | 3.0170 mL | 6.0341 mL | |
| 10 mM | 0.3017 mL | 1.5085 mL | 3.0170 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.